HER2 Support Group Forums - View Single Post

StephN · 12-21-2010, 02:55 PM

Mayo Clinic
Cancer
TapImmune Inc. has signed an exclusive Licensing Option agreement with Mayo Clinic, Rochester, MN, for clinical development of a breast cancer vaccine technology. The option to license this technology can be exercised after Phase I clinical trials under terms agreed between Mayo Clinic and TapImmune. Mayo Clinic will conduct a Phase I clinical trial in breast cancer patients who have a form of breast cancer that express Her2/neu receptors (also called Her2/neu breast cancer). Keith Knutson, M.D. will serve as Principal Investigator.
Her2/neu receptor related cancer is a very aggressive form of breast cancer that affects a subset of breast cancer patients. It is a well established therapeutic target, which helps our development goals from a regulatory standpoint. For example, Herceptin (a Her2/neu inhibitor by Genentech) is an approved drug with annual sales in excess of $4 Billion. </STRONG>
There are ongoing vaccine trials targeting Her2/neu. The major disadvantage (as we understand) of technologies that are currently in development are their inability to cover all or a majority of Her2/neu cancer patients and their ability for long-term protection. Some of them seem to be effective only in a subset of Her2/neu cancer patients due to the nature of the peptide epitopes used. Along with Mayo we believe this technology is could cover up to 90% of the Her2/neu patients and last a very long time (if not a life time), which is an improvement that could cover an additional 30% of the population who may not be covered by the other technologies that are currently in development. </STRONG>
Dr Glynn Wilson, Executive Chairman of TapImmune, stated, “The option to license this technology from Mayo Clinic represents a significant opportunity to add to our cancer vaccine portfolio and clinical research programs. We believe that this technology offers a number of advantages in the development of a breast cancer vaccine for a broad patient population

12-21-2010, 02:55 PM	#1
StephN Senior Member Join Date: Nov 2004 Location: Misty woods of WA State Posts: 4,128	New HER2 vaccine trial to watch for Mayo Clinic Cancer TapImmune Inc. has signed an exclusive Licensing Option agreement with Mayo Clinic, Rochester, MN, for clinical development of a breast cancer vaccine technology. The option to license this technology can be exercised after Phase I clinical trials under terms agreed between Mayo Clinic and TapImmune. Mayo Clinic will conduct a Phase I clinical trial in breast cancer patients who have a form of breast cancer that express Her2/neu receptors (also called Her2/neu breast cancer). Keith Knutson, M.D. will serve as Principal Investigator. Her2/neu receptor related cancer is a very aggressive form of breast cancer that affects a subset of breast cancer patients. It is a well established therapeutic target, which helps our development goals from a regulatory standpoint. For example, Herceptin (a Her2/neu inhibitor by Genentech) is an approved drug with annual sales in excess of $4 Billion. </STRONG> There are ongoing vaccine trials targeting Her2/neu. The major disadvantage (as we understand) of technologies that are currently in development are their inability to cover all or a majority of Her2/neu cancer patients and their ability for long-term protection. Some of them seem to be effective only in a subset of Her2/neu cancer patients due to the nature of the peptide epitopes used. Along with Mayo we believe this technology is could cover up to 90% of the Her2/neu patients and last a very long time (if not a life time), which is an improvement that could cover an additional 30% of the population who may not be covered by the other technologies that are currently in development. </STRONG> Dr Glynn Wilson, Executive Chairman of TapImmune, stated, “The option to license this technology from Mayo Clinic represents a significant opportunity to add to our cancer vaccine portfolio and clinical research programs. We believe that this technology offers a number of advantages in the development of a breast cancer vaccine for a broad patient population __________________ "When I hear music, I fear no danger. I am invulnerable. I see no foe. I am related to the earliest times, and to the latest." H.D. Thoreau Live in the moment. MY STORY SO FAR ~~~~ Found suspicious lump 9/2000 Lumpectomy, then node dissection and port placement Stage IIB, 8 pos nodes of 18, Grade 3, ER & PR - Adriamycin 12 weekly, taxotere 4 rounds 36 rads - very little burning 3 mos after rads liver full of tumors, Stage IV Jan 2002, one spot on sternum Weekly Taxol, Navelbine, Herceptin for 27 rounds to NED! 2003 & 2004 no active disease - 3 weekly Herceptin + Zometa Jan 2005 two mets to brain - Gamma Knife on Jan 18 All clear until treated cerebellum spot showing activity on Jan 2006 brain MRI & brain PET Brain surgery on Feb 9, 2006 - no cancer, 100% radiation necrosis - tumor was still dying Continue as NED while on Herceptin & quarterly Zometa Fall-2006 - off Zometa - watching one small brain spot (scar?) 2007 - spot/scar in brain stable - finished anticoagulation therapy for clot along my port-a-catheter - 3 angioplasties to unblock vena cava 2008 - Brain and body still NED! Port removed and scans in Dec. Dec 2008 - stop Herceptin - Vaccine Trial at U of W begun in Oct. of 2011 STILL NED everywhere in Feb 2014 - on wing & prayer 7/14 - Started twice yearly Zometa for my bones Jan. 2015 checkup still shows NED 2015 Neuropathy in feet - otherwise all OK - still NED. Same news for 2016 and all of 2017. Nov of 2017 - had small skin cancer removed from my face. Will have Zometa end of Jan. 2018.